Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Apr;23 Suppl 1(Suppl 1):S29-36.
doi: 10.1089/jamp.2009.0768.

Evaluation of the Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis

John Denyer  1 , Ivan Prince, Emma Dixon, Penny Agent, Jennifer Pryor, Margaret Hodson
Affiliations
Clinical Trial

Evaluation of the Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis

John Denyer et al. J Aerosol Med Pulm Drug Deliv. 2010 Apr.

Abstract

Background: Adaptive Aerosol Delivery (AAD) systems provide efficient drug delivery and improved lung deposition over conventional nebulizers by combining real-time analyses of patient breathing patterns and precisely timed aerosol delivery. Delivery and deposition are further enhanced by breathing techniques involving slow, deep inhalations.

Methods: This exploratory study assessed the acceptability of slow, deep inhalations in 20 patients with cystic fibrosis (CF) during up to eight simulated nebulizer treatments with the I-neb AAD System. The breathing maneuver, Target Inhalation Mode (TIM) breathing, involved the lengthening of the patient's inhalation time over successive breaths with guidance from auditory and tactile (vibratory) feedback from the device.

Results: At the end of the first treatment, most patients felt that the instructions were easy to understand (90%) and that the vibratory feedback was pleasant (65%). Half of the patients found the procedure to be comfortable. At the end of the final treatment, most patients felt that the breathing maneuver was easy to understand (90%) and use (80%), but that the duration of the breath was too long (100%). Logged data revealed that 90% of patients were able to comply with the breathing maneuver. The two patients unable to comply had a forced vital capacity of <1.75 L. The average treatment time decreased from 288.4 to 141.6 sec during the first and final treatments, respectively.

Conclusions: This study provides preliminary evidence of the acceptability of the TIM breathing maneuver in patients with CF and their ability to perform repeated TIM breathing during simulated nebulizer therapy with the I-neb AAD System.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
The figure shows the study equipment, which consisted of a customized I-neb AAD System connected to a personal computer operating the I-neb AAD System software. A flow restrictor, a pneumotach, and a vibration device had been built into the customized I-neb AAD System handset.
FIG. 2.
FIG. 2.
A graphic presentation of breath patterns for Tidal Breathing Mode (TBM) and Target Inhalation Mode (TIM).
FIG. 3.
FIG. 3.
The figure shows a comparison between the patients' baseline forced vital capacity (FVC) and their opinions on breath length after the first treatment.
FIG. 4.
FIG. 4.
A graphic presentation of logged data for one of the patients including inhalation time (♦), pulse time (▪), and Inhalation Target Time (▴) data. The data were collected over five placebo treatments.
FIG. 5.
FIG. 5.
A graphic presentation of the mean treatment times and the mean number of inhalations during the eight study treatments. The number of inhalations decreased in parallel with the mean treatment time.
See this image and copyright information in PMC

References

    1. Lewis PA. The epidemiology of cystic fibrosis. In: Hodson ME, editor; Geddes DM, editor. Cystic Fibrosis. Chapman and Hall; London: 1995. pp. 1–13.
    1. Sheppard MN. The pathology of cystic fibrosis. In: Hodson ME, editor; Geddes DM, editor. Cystic Fibrosis. Chapman and Hall; London: 1995. pp. 131–149.
    1. Geller DE. Choosing a nebulizer for cystic fibrosis applications. Curr Opin Pulm Med. 1997;3:414–419. - PubMed
    1. Geller DE. Eigen H. Fiel SB. Clark A. Lamarre AP. Johnson CA. Konstan MW. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Pediatr Pulmonol. 1998;25:83–87. - PubMed
    1. Le Brun PPH. de Boer AH. Gjaltema D. Hagedoorn P. Heijerman HGM. Frijlink HW. Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer. Int J Pharm. 1999;189:205–214. - PubMed

Publication types